TG Therapeutics Stock News

TG Therapeutics' Q3'23 net sales of Briumvi of $25.1M seemed to impress the market. Q3'23 sales of Briumvi were aided by J-code availability and increases in payor coverage. Q4'23 sales are hard to pr

The average of price targets set by Wall Street analysts indicates a potential upside of 127.8% in TG Therapeutics (TGTX). While the effectiveness of this highly sought-after metric is questionable, t

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - C

The company reported Q3 results that were much better than expected. An up-front licensing payment from Neuraxpharm was a big factor in these surprisingly good results.

TG Therapeutics Inc (NASDAQ:TGTX) stock is soaring today, after the biopharmaceutical name's third-quarter results smashed analyst expectations.

Conference call to be held Wednesday, November 1, 2023, at 8:30 AM ET Conference call to be held Wednesday, November 1, 2023, at 8:30 AM ET

TG Therapeutics, Inc. stock has declined by 75% since its approval highs, with little hope of recovery. The company's fortunes have been tied to its earnings, with a Q2 miss causing a significant drop

TG Therapeutics (NASDAQ: TGTX) stock price sell-off continued this week as concerns about the rising competition continued. The shares plunged to a low of $7.53 on Wednesday, much lower than the year-

TG Therapeutics has transitioned from a developer of oncology drugs to a commercial-stage neurology company with the approval of its multiple sclerosis (MS) drug, Briumvi. Briumvi, the flagship drug o

Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET

Fireside chat scheduled for Monday, September 11, 2023, at 10:30 AM ET Fireside chat scheduled for Monday, September 11, 2023, at 10:30 AM ET

After I spent many years following Wall Street, there are a few characteristics about the “big money”  that stand out for me. One of these traits is that many if not most large investors are very

Following a disappointing outcome for the second quarter, shares of biotechnology firm TG Therapeutics (NASDAQ: TGTX ) suffered a catastrophic loss. Specializing in Briumvi — a therapeutic for the t

NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, August 1, 2023, at 8:30 AM ET to discuss results for t

The launch of Briumvi is off to a solid start, but the stock pulled back recently and fell more after Roche reported positive phase 3 results of subcutaneously administered Ocrevus. The improved conve